Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00606034 · ClinicalTrials.gov registry record · Phase 4
U-500R Insulin In Type 2 Diabetes With Severe Insulin Resistance Via Omnipod
A Phase 4 study, sponsored by Mountain Diabetes and Endocrine Center.
- Completed
- Registry status
- Phase 4
- Development phase
- 21
- Enrollment target
NCT00606034: Completed Phase 4 study, sponsored by Mountain Diabetes and Endocrine Center.
NCT00606034 is a Phase 4 study that has completed, run by Mountain Diabetes and Endocrine Center. The registered enrollment target is 21 participants, below the 518-participant average among 9,235 other Phase 4 trials with a reported enrollment target (96% lower). According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT00606034, a Phase 4 study, has completed, sponsored by Mountain Diabetes and Endocrine Center.
- COMPLETED
- Registry status
- Phase 4
- Development phase
- 21 participants
- Enrollment target
Study Summary
Patients with Type 2 diabetes and severe insulin resistance with very large insulin requirements who have failed all previous insulin regimens using non-concentrated forms of insulin (U100 insulin formulations) will receive 5X concentrated insulin (U500 regular insulin)infused via insulin pump.
Primary Outcome
HbA1c is expressed as a percentage. This measurement represents an average of plasma glucose concentration for about 3 months. We will report the change in HbA1c measured at 12 months vs Baseline.
Interventions
- DRUG U-500 Insulin delivered by Omnipod (disposable insulin pump)
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 21 participants |
| Start Date | 2007-12 |
| Est. Completion | 2009-07 |
| Phase | Phase 4 |
What the finished NCT00606034 record still lists
NCT00606034 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 21 participants, a relatively small participant target, below the 518-participant average among 9,235 other Phase 4 trials with a reported enrollment target (96% lower).
The record links to 0 conditions, and to 1 intervention - of which U-500 Insulin delivered by Omnipod (disposable insulin pump) is the first listed.
NCT00606034 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT00606034 about?
NCT00606034 is a clinical study titled "U-500R Insulin In Type 2 Diabetes With Severe Insulin Resistance Via Omnipod". Patients with Type 2 diabetes and severe insulin resistance with very large insulin requirements who have failed all previous insulin regimens using non-concentrated forms of insulin (U100 insulin formulations) will receive 5X concentrated insulin (U500 regular insulin)infused via insulin pump.
What is the current status of trial NCT00606034?
This trial is currently completed. It is a Phase 4 study. The enrollment target is 21 participants. The study started on 2007-12. Estimated completion is 2009-07.
What interventions are being tested in trial NCT00606034?
The interventions under investigation include: U-500 Insulin delivered by Omnipod (disposable insulin pump) (DRUG).
Who is sponsoring clinical trial NCT00606034?
This trial is sponsored by Mountain Diabetes and Endocrine Center, which has 3 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT00606034's enrollment target sits among peer trials
21 1742nd of 2000 higher than 248 of 2,000 other Phase 4 trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Phase 4 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT02447874 · 21 participants · Phase 1
Arginine Therapy for the Treatment of Pain in Children With Sickle Cell Disease
- NCT03826992 · 21 participants · Phase 1
Venetoclax Combined With Vyxeos (CPX-351) for Participants With Relapsed or Refractory Acute Leukemia
- NCT04107077 · 21 participants · Phase 2
Phase II Study of the Effects of Laparoscopic Hyperthermic Intraperitoneal Chemotherapy (HIPEC) in Patients With Advanced Gastric Cancer
- NCT04158635 · 21 participants · Phase 1
Gemcitabine, Nab-Paclitaxel, and Bosentan for the Treatment of Unresectable Pancreatic Cancer
Similar registry start date
- NCT05988463 · started 2027-01-01 · Phase 1
Dose-Escalation Study of Artesunate Patients With IPF
- NCT07219706 · started 2026-12-10 · NA
Dietary Fiber and Time Restricted Eating
- NCT02831335 · started 2026-12-01
Technical Development of Multi-Parametric Renocerebral MRI
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia